ASTM F2721-09(2023) PDF

Overview

ASTM F2721-09(2023), published by ASTM International, is a standard guide providing methodologies for the preclinical in vivo evaluation of tissue-engineered medical products (TEMPs) used in the repair or regeneration of critical-size segmental bone defects. This guide is an essential resource for the preclinical assessment of TEMPs, including both natural and synthetic biomaterials, and those incorporating cells or biologically active agents. By focusing on animal models and detailed study designs, it supports research aimed at translating innovative bone repair solutions to clinical applications.

Critical-size segmental defects are challenging bone injuries that will not heal without medical intervention, establishing a stringent and clinically relevant benchmark for evaluating the effectiveness of new bone regenerative materials.

Key Topics

• Animal Models: The guide outlines the use of various animal species-rat, rabbit, dog, sheep, and goat-to model critical-size bone defects. The choice of species and defect site depends on factors such as anatomical similarity to humans, age, skeletal maturity, and intended clinical application.
• Surgical Considerations: Recommendations are made for surgical techniques, defect creation, periosteum management, fixation methods, and post-operative care, ensuring reproducibility and animal welfare.
• Study Design and Controls: Guidance is provided on cohort selection, chromosomal sex, sample sizes, dietary considerations, pathology models, and the importance of including empty-control groups to verify defect criticality.
• Outcome Analysis: The guide briefly describes outcome measures, including radiographic, histologic, and mechanical analysis to assess bone repair and regeneration.
• Regulatory Compliance: Emphasis is placed on following FDA Good Laboratory Practice (GLP) Regulations (21 CFR 58), biocompatibility and cytotoxicity testing standards, and relevant regulatory guidelines for devices, biologics, and drugs.

Applications

ASTM F2721-09(2023) applies to:

• Medical Device Development: Assisting manufacturers and researchers in generating robust preclinical data that supports regulatory submissions for bone repair products.
• Tissue Engineering Research: Providing a foundation for evaluating novel TEMPs, including biomaterial scaffolds with or without added cells, growth factors, or gene therapies.
• Comparative Studies: Facilitating head-to-head comparisons between new bone repair technologies and established standards such as autografts.
• Regulatory Submissions: Data generated in accordance with this guide can be used for FDA Investigational Device Exemption (IDE), Premarket Approval (PMA), 510(k) clearances, as well as biologics and drug applications (IND and BLA).
• Academic Research: Supporting methodical, reproducible animal research in bone regeneration, enabling better translation from preclinical findings to human clinical practice.

Related Standards

For a comprehensive and compliant preclinical bone evaluation program, ASTM F2721-09(2023) references several related standards and guidelines, including:

• ASTM F561: Practice for Retrieval and Analysis of Medical Devices, and Associated Tissues and Fluids
• ASTM F565: Practice for Care and Handling of Orthopedic Implants and Instruments
• ASTM F895: Test Method for Agar Diffusion Cell Culture Screening for Cytotoxicity
• ASTM F981: Practice for Assessment of Compatibility of Biomaterials for Surgical Implants
• ASTM F1983: Practice for Assessment of Selected Tissue Effects of Absorbable Biomaterials
• ASTM F2150: Guide for Characterization and Testing of Biomaterial Scaffolds Used in Regenerative Medicine
• 21 CFR Part 58: Good Laboratory Practice for Nonclinical Laboratory Studies
• 21 CFR 610.12: General Biological Products Standards-Sterility

Practical Value

By following ASTM F2721-09(2023):

• Researchers gain a well-documented protocol for the challenging in vivo assessment of bone regeneration.
• Product developers speed up the pathway from innovation to the clinic by adhering to recognized animal models and regulatory expectations.
• Regulatory submissions are strengthened with standardized, high-quality preclinical data.
• The comparability and reliability of results across studies and institutions are enhanced.

Keywords: bone regeneration, tissue-engineered medical products, in vivo models, animal studies, critical-size defect, bone repair, preclinical testing, biocompatibility, bone healing, ASTM standards.